List of Excipients in Branded Drug SAVAYSA

« Back to Dashboard

Last updated: August 29, 2026

SAVAYSA (edoxaban tosylate) has a relatively conventional immediate-release tablet platform. Its commercial opportunity is less likely to come from copying the core excipient formula than from developing differentiated delivery formats, cost-optimized generic formulations, pediatric or swallowing-friendly products, and excipient systems that support reliable dissolution across manufacturing sites. The main technical constraints are dose proportionality, rapid dissolution, stability of edoxaban tosylate, and regulatory demonstration of pharmaceutical equivalence.

SAVAYSA Excipient Strategy and Commercial Opportunities for Edoxaban

What is SAVAYSA and which excipients does it contain?

SAVAYSA is the U.S. brand name for edoxaban tablets, an oral direct factor Xa inhibitor marketed by Daiichi Sankyo. The product is approved for stroke and systemic embolism prevention in nonvalvular atrial fibrillation and for treatment of deep vein thrombosis and pulmonary embolism after five to 10 days of parenteral anticoagulation.[1]

The marketed product is an immediate-release, film-coated tablet in 15 mg, 30 mg, and 60 mg strengths. The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Publicly identified excipient or material	Primary role
Tablet core	Mannitol	Diluent and mouthfeel modifier
Tablet core	Pregelatinized starch	Binder and disintegrant support
Tablet core	Crospovidone	Superdisintegrant
Tablet core	Hydroxypropyl cellulose	Binder
Tablet core	Magnesium stearate	Lubricant
Film coat	Hypromellose	Film-forming polymer
Film coat	Talc	Anti-tacking and coating aid
Film coat	Titanium dioxide	Opacifier
Film coat	Ferric oxide colorants, where applicable	Tablet-strength identification
Other coating materials	Product-specific coating and polishing materials	Appearance and handling

The precise quantitative composition is not disclosed in the U.S. label. Generic developers must establish their own quantitative formula and demonstrate compliance with applicable FDA quality and bioequivalence requirements.[1,2]

How does the SAVAYSA excipient system work?

The excipient platform is designed for rapid disintegration and dissolution rather than sustained release. Mannitol provides bulk and compressibility, while pregelatinized starch and hydroxypropyl cellulose support granule formation and tablet mechanical strength. Crospovidone promotes water penetration and tablet breakup. Magnesium stearate reduces tooling friction but must be controlled because excessive lubrication can slow wetting and dissolution.

The formulation strategy has four commercial advantages:

1. It uses widely available compendial excipients.
2. It supports conventional high-speed tablet manufacturing.
3. It avoids dependence on a proprietary modified-release polymer system.
4. It allows multiple tablet strengths without requiring a complex delivery platform.

The main development risk is balancing tablet hardness, friability, disintegration, and dissolution. Edoxaban products must also maintain dose uniformity because the 15 mg, 30 mg, and 60 mg strengths are clinically distinct and have different dose-reduction implications.

What excipient properties matter most for edoxaban tablets?

Dissolution performance

For a direct oral anticoagulant, dissolution consistency is commercially important because variability in exposure can affect anticoagulant response. Crospovidone level, starch gelatinization, granulation endpoint, lubricant concentration, compression force, and coating weight can all influence dissolution.

A generic formulation should control:

• Particle-size distribution of edoxaban tosylate.
• Drug loading and blend uniformity.
• Granule porosity.
• Magnesium stearate blending time.
• Tablet hardness and disintegration.
• Film-coat weight gain.
• Dissolution across relevant pH conditions.

The formulation should be tested against the reference product across multiple dissolution media. Similarity in a single medium is unlikely to provide sufficient development confidence for a product with multiple strengths and a narrow therapeutic role.

Stability and moisture control

Edoxaban tosylate is supplied as a crystalline drug substance. Excipient water activity, packaging permeability, and coating integrity can affect long-term stability. Mannitol is generally attractive where low hygroscopicity is useful, while starch-based excipients require tighter moisture control during granulation and storage.

Commercially relevant packaging options include high-barrier blister packs and high-density polyethylene bottles with desiccant systems. The optimal choice depends on stability data, manufacturing cost, market requirements, and whether the product is intended for hospital, retail, or adherence-focused channels.

Manufacturability

The reference excipient combination is compatible with direct compression or wet-granulation approaches, depending on drug-substance properties and target loading. A generic developer can pursue a lower-cost formulation using:

• Co-processed mannitol-starch systems.
• Direct-compression grades of mannitol.
• Alternative superdisintegrants.
• Lower-cost film-coating premixes.
• Optimized lubricant concentrations.
• Continuous manufacturing or high-shear wet granulation.

Substitution is commercially attractive only if the resulting product preserves dissolution, stability, tablet robustness, and bioequivalence. Excipient changes that reduce raw-material cost but create process variability can increase total cost through failed batches, supplemental studies, or regulatory review questions.

What formulations are protected by SAVAYSA-related intellectual property?

Publicly available product information establishes the marketed product’s dosage forms and excipient identity, but it does not establish that every listed excipient or the disclosed combination remains patent-protected. Pharmaceutical companies typically protect a drug product through several overlapping categories:

IP category	Relevance to edoxaban
Compound patents	Protection for edoxaban and related chemical entities
Salt and crystalline-form patents	Protection for edoxaban tosylate and solid-state forms
Formulation patents	Protection for tablet composition, dissolution, stability, or bioavailability
Method-of-use patents	Protection for dosing, patient selection, renal impairment, or treatment settings
Manufacturing patents	Protection for crystallization, purification, granulation, or tablet production
Regulatory exclusivity	FDA exclusivity independent of patent scope

An excipient combination can be claimed in a formulation patent, but the mere appearance of an excipient in the FDA label does not establish enforceable exclusivity. Freedom-to-operate analysis requires review of issued claims, patent-family status, terminal disclaimers, reexamination or post-grant proceedings, and jurisdiction-specific expiration dates.

When does SAVAYSA lose exclusivity and what is the generic entry risk?

SAVAYSA received U.S. approval in January 2015. Its five-year new chemical entity exclusivity therefore expired in 2020, subject to the specific regulatory treatment of the active ingredient and any other applicable exclusivity.[1,3]

Patent-based generic entry depends on the Orange Book-listed patents and the outcome of any Paragraph IV certifications. The commercial assessment should separate three dates:

Timing category	Commercial significance
NCE exclusivity expiry	Determines when an ANDA may generally be submitted without NCE blocking
Listed patent expiry	Determines the earliest ordinary generic launch date, subject to challenge
30-month stay or litigation resolution	Can delay approval after a qualifying Paragraph IV notice

For SAVAYSA, an ANDA applicant would normally evaluate Paragraph III certification, Paragraph IV certification, or a section viii statement for any listed method-of-use patent. A formulation patent that covers only a specific use or dosage regimen may not block a generic seeking approval for unclaimed indications, provided the labeling can be appropriately carved out.

The economic risk is moderated by the presence of several direct oral anticoagulants, including apixaban, rivaroxaban, dabigatran, and warfarin. A generic edoxaban entrant would compete against established products with greater market recognition and, in some cases, broader indication or reimbursement coverage.

What Paragraph IV challenges and litigation affect SAVAYSA?

A complete current assessment of Paragraph IV filings, patent litigation, settlements, and launch dates requires live review of FDA Orange Book records, ANDA litigation dockets, and current patent-family data. Public product labeling alone cannot establish the current litigation position.

The relevant legal questions are:

• Which patents are listed for the specific SAVAYSA strengths?
• Are listed claims directed to the compound, salt, formulation, or method of use?
• Has any ANDA applicant provided a Paragraph IV notice?
• Was a district-court action filed within 45 days?
• Is a 30-month stay active, expired, or terminated?
• Does a settlement provide a licensed entry date?
• Does the agreement restrict authorized-generic supply or manufacturing?

These questions should be resolved by matching Orange Book listings to Patent Center records and district-court complaints. Patent expiration should not be inferred from the product launch date or from the date of FDA approval alone.

How strong is the SAVAYSA patent estate from an excipient perspective?

The excipient-related estate is likely less difficult to design around than a complex long-acting or biologic delivery system because the commercial product is a conventional immediate-release tablet. A generic developer can usually select alternative excipients if it achieves pharmaceutical equivalence and bioequivalence.

The strongest potential barriers would be claims that combine:

• A specific edoxaban salt or crystalline form.
• A narrow dissolution profile.
• A defined particle-size distribution.
• A particular stabilizer or moisture-control system.
• A manufacturing sequence linked to impurity control.
• A formulation that solves a demonstrated bioavailability or stability problem.

Broad claims directed only to common excipients are vulnerable to validity and design-around challenges if the formulation lacks a clear technical effect. Narrow claims supported by comparative dissolution, stability, or pharmacokinetic data may create a more meaningful barrier.

What commercial opportunities exist for alternative edoxaban formulations?

Low-cost generic immediate-release tablets

The most direct opportunity is a conventional generic tablet using a lower-cost, supply-secure excipient platform. Manufacturers can compete through:

• Fewer specialized raw materials.
• Regional excipient sourcing.
• Improved tablet yield.
• Reduced coating time.
• High-throughput compression.
• Pack-size and bottle optimization.

The product must preserve the reference strength, appearance requirements where applicable, dissolution, assay, impurities, and stability profile.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, older adults, and patients receiving anticoagulation after hospitalization. A successful product would need to address the bitter taste of edoxaban and maintain dose accuracy at low tablet mass.

Candidate excipient systems include mannitol-based rapidly dissolving matrices, crospovidone, low-substituted hydroxypropyl cellulose, flavor systems, sweeteners, and taste-masking coatings. The principal development challenge is avoiding delayed or incomplete release from taste-masking layers.

Sprinkle or dispersible dosage forms

A capsule or tablet that can be dispersed in water or administered with soft food could improve administration for patients who cannot swallow conventional tablets. The formulation would need validated instructions for dispersion, dose recovery, compatibility with food vehicles, and stability after preparation.

This product could have commercial value in long-term care, home health, and pediatric settings. The regulatory pathway would depend on whether the dosage form is treated as a new dosage form, a line extension, or a generic equivalent.

Pediatric formulation

Edoxaban has potential pediatric relevance in thromboembolic disorders, but a pediatric product would require age-appropriate dosing, palatability, dose flexibility, and clinical support. A multiparticulate suspension or mini-tablet platform could provide more precise dosing than a conventional adult tablet.

Commercial value would depend on regulatory requirements, payer coverage, pediatric indication strategy, and competition from other anticoagulants with established pediatric formulations.

Fixed-dose combinations

A fixed-dose combination with another cardiovascular medicine could simplify therapy, but the clinical and regulatory burden would be high. Anticoagulation is often adjusted independently from blood-pressure, lipid, or rhythm-control therapy. A fixed combination could therefore reduce dose flexibility and create avoidable safety concerns.

Hospital and adherence packaging

Excipient innovation is not required for every commercial opportunity. Calendar blister packs, unit-dose packaging, color differentiation, and adherence-oriented pack sizes can create value while reducing formulation risk. Such opportunities are particularly relevant for a drug with multiple strengths and clinically important dose adjustments.

How does SAVAYSA compare with competing anticoagulants?

Product	Active ingredient	Dosage-form opportunity	Competitive consideration
SAVAYSA	Edoxaban	Immediate-release tablet, ODT, dispersible form	Smaller commercial base than leading DOACs
Eliquis	Apixaban	Tablet and pediatric development potential	Strong brand and broad adoption
Xarelto	Rivaroxaban	Tablet, suspension, granule-related opportunities	Multiple indications and dosage forms
Pradaxa	Dabigatran etexilate	Capsule and pellet-based delivery	Distinct formulation and storage profile
Warfarin	Warfarin sodium	Tablet and compounded liquid	Low cost, monitoring burden, narrow therapeutic margin

The main advantage of an edoxaban formulation program is the possibility of obtaining a differentiated product without reproducing the complexity of a modified-release system. The main disadvantage is market access. Formulation differentiation alone may not overcome prescriber and payer preference for higher-volume competing anticoagulants.

What is the FDA regulatory status of SAVAYSA?

SAVAYSA is FDA-approved as an oral tablet. The label includes renal-function-related dosing restrictions and a warning that its use is not recommended in patients with creatinine clearance above 95 mL/min for nonvalvular atrial fibrillation because of reduced relative efficacy compared with warfarin in that population.[1]

For a generic or line extension, regulatory priorities include:

• Pharmaceutical equivalence to the reference listed drug.
• Bioequivalence under the applicable FDA product-specific guidance.
• Comparative dissolution.
• Impurity and degradation-product control.
• Strength-specific content uniformity.
• Stability in commercial packaging.
• Labeling consistency and permissible indication carve-outs.

A new dosage form, pediatric product, or delivery system could require more extensive clinical, pharmacokinetic, or human-factors evidence than a standard ANDA tablet.

What manufacturing and IP barriers affect commercial entry?

The active pharmaceutical ingredient and its solid-state properties may create more meaningful barriers than the excipient list. Key manufacturing controls include polymorph or salt-form consistency, particle engineering, impurity control, blend uniformity, and scale-up reproducibility.

Potential barriers include:

• Limited suppliers of qualified edoxaban tosylate.
• Dependence on a specific crystalline form.
• High-cost analytical methods for solid-state characterization.
• Dissolution sensitivity to particle size.
• Patent claims covering salt, polymorph, or manufacturing steps.
• Regulatory changes triggered by a novel excipient or dosage form.
• Global differences in patent and data-exclusivity status.

Geographic strategy matters. A formulation that is commercially viable in the United States may face different patent, substitution, pricing, and registration conditions in Europe, Japan, China, India, and emerging markets. Generic companies should assess each market independently rather than treating U.S. patent expiry as a global entry date.

What is the revenue exposure and commercial attractiveness of an edoxaban excipient program?

An edoxaban excipient program has moderate technical attractiveness and uncertain market attractiveness. A conventional generic tablet offers the lowest development risk but also the greatest price pressure. A differentiated formulation can improve margin and create a longer commercial window, but it may require clinical or regulatory investment.

The most attractive opportunities are:

1. A cost-efficient generic tablet with reliable multi-strength manufacturing.
2. A swallowing-friendly ODT or dispersible product.
3. A pediatric or flexible-dose formulation.
4. Unit-dose packaging for institutional and adherence markets.
5. Regional licensing of formulation technology to generic manufacturers.

The least attractive strategy is a cosmetic excipient substitution without a clear patient, manufacturing, or regulatory advantage. Such a product may incur development costs without creating meaningful switching value.

Key Takeaways

• SAVAYSA is an immediate-release edoxaban tosylate film-coated tablet in 15 mg, 30 mg, and 60 mg strengths.
• The public excipient platform uses mannitol, pregelatinized starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, and conventional film-coating materials.
• The principal generic opportunity is a cost-optimized tablet with equivalent dissolution and bioavailability.
• ODT, dispersible, sprinkle, and pediatric formats offer greater differentiation but carry higher regulatory and development risk.
• The core excipient formula is unlikely to be the primary IP barrier unless linked to a defined technical effect, dissolution profile, solid form, or manufacturing process.
• Current Paragraph IV, Orange Book, patent-expiry, and settlement conclusions require jurisdiction-specific review of live FDA and court records.
• Commercial success will depend more on market access, payer substitution, supplier economics, and dosage-form differentiation than on simple excipient replacement.

FAQs

Can a generic manufacturer use the same excipients as SAVAYSA?

Yes. Use of the same excipients does not by itself violate patent rights. The manufacturer must still satisfy pharmaceutical-equivalence, bioequivalence, quality, labeling, and patent-certification requirements.

Is mannitol necessary in an edoxaban tablet?

No. Mannitol is part of the marketed product’s disclosed excipient system, but a generic developer may evaluate other suitable diluents if the formulation meets performance and regulatory requirements.

Could an edoxaban liquid formulation create a new market?

Potentially. A liquid or dispersible product could target dysphagia, institutional care, and pediatric use. It would require demonstrated dose uniformity, stability, palatability, administration instructions, and an appropriate FDA regulatory pathway.

Are excipient patents more important than edoxaban compound patents?

Usually not for a conventional immediate-release generic. Compound, salt, polymorph, formulation, and manufacturing patents may present greater entry risk than claims limited to common excipients.

Which excipient strategy offers the fastest route to market?

A conventional immediate-release tablet using compendial excipients and a manufacturing process aligned with the reference product generally offers the fastest development path. Novel delivery systems can provide greater differentiation but usually require more extensive regulatory support.

References

1. U.S. Food and Drug Administration. (2023). Savaysa (edoxaban tosylate) prescribing information. Daiichi Sankyo, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). New chemical exclusivity and generic drug approval provisions. FDA.